Blood Leukocyte Counts in Alzheimer Disease

• Published in: JAMA network open Vol. 5; no. 10; p. e2235648
• Main Authors: Luo, Jiao, Thomassen, Jesper Qvist, Nordestgaard, Børge G, Tybjærg-Hansen, Anne, Frikke-Schmidt, Ruth
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 03-10-2022
• Subjects: Aged; Alzheimer Disease - epidemiology; Alzheimer's disease; Biobanks; Cohort analysis; Cohort Studies; Consortia; Dementia; Electrolytes; Female; Genetics and Genomics; Genomics; Humans; Immune system; Leukocyte Count; Leukocytes; Male; Mendelian Randomization Analysis - methods; Middle Aged; Online Only; Original Investigation; Pathogenesis; Prospective Studies
• ISSN: 2574-3805; 2574-3805
• DOI: 10.1001/jamanetworkopen.2022.35648

Emerging evidence implicates a role for neuroinflammation in Alzheimer disease (AD) pathogenesis, predominantly involving the innate immune system. Blood leukocyte counts are easily accessible markers of immune function; however, their association with the risk of AD is unknown.
To investigate the observational and genetic associations between types of blood leukocytes and risk of AD.
In a cohort study comprising observational and genetic analyses, the Copenhagen General Population Study prospective cohort (n = 101 582) was used for the observational analyses. For the genetic studies, nonlinearity was first evaluated for the association between leukocyte cell counts and AD risk using individual-level data from the UK Biobank (n = 365 913). Subsequently, a 2-sample mendelian randomization framework was applied using genetic instruments for blood leukocyte counts (n = 563 085); for AD, the European Alzheimer & Dementia Biobank was used, including 85 934 individuals with AD and 401 577 controls and the International Genomics of Alzheimer's Project, including 21 982 individuals with AD and 41 944 controls.
Observational and genetically determined types of blood leukocyte counts.
Hazard ratios (HRs) and 95% CIs for AD of cell count percentile groups in observational studies and odds ratios (ORs) and 95% CIs for AD per 1 SD genetically determined cell counts.
This cohort study included 101 582 participants (55 891 [55.0%] women) with a median age of 58 years (IQR, 48-67 years); of these, 1588 individuals developed AD. Multivariable-adjusted HRs for participants in the less than 5th vs the 25th to 75th (reference) percentile group were 1.24 (95% CI, 0.99-1.54) for blood monocytes and 1.25 for blood eosinophils (95% CI, 1.05-1.50). For participants in the greater than 95th vs the 25th to 75th percentile group, the HR was 1.30 (95% CI, 1.06-1.61) for blood neutrophils. Genetically, no evidence favored possible nonlinear associations. The ORs for AD per 1-SD decrease in genetically determined blood monocytes were 1.04 (95% CI, 1.00-1.10) in the European Alzheimer & Dementia Biobank consortium and 1.09 (95% CI, 1.01-1.17) in the International Genomics of Alzheimer's Project consortium. Using mendelian randomization, sensitivity analyses and multivariable analysis showed similar results.
The findings of this study suggest that low blood monocyte counts are associated with increased AD risk. These findings highlight a potential role of the innate immune system in AD pathogenesis.